checkAd

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting

Nachrichtenquelle: globenewswire
26.02.2021, 14:00  |  110   |   |   

Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes

By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improve S. Pneumoniae-Related Hospital Clinical Outcomes

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the presentation of a late-breaking poster at the 2021 American Academy of Allergy, Asthma & Immunology Conference (“AAAAI”) Virtual Annual Meeting taking place February 26 – March 1, 2021. The abstract has been published online in a supplement to The Journal of Allergy and Clinical Immunology.

“Vulnerable patient populations, including the immune compromised, remain at risk of S. pneumoniae infection despite the availability of FDA-approved vaccines,” said Adam Grossman, President and Chief Executive Officer of ADMA. “These data underscore the exciting prospect of bridging the time between vaccination and seroconversion to achieve protective levels of antibody with a targeted, plasma derived hyperimmune globulin to ensure protection against infection for at-risk patients in hospital and outpatient settings. Our existing intellectual property portfolio includes issued patents on the composition of matter and methods of use for producing a standardized hyperimmune globulin targeted to the most common 23 serotypes of S. pneumoniae bacteria. We will continue to evaluate opportunities to expand our pipeline and future product offerings to maximize value for our shareholders and to address the unmet needs of our targeted patient populations.”

Details for the AAAAI 2021 presentation are as follows:

Abstract Title: Results of Cross-Stakeholder Qualitative Study on the Potential Utility of a Hyperimmune Globulin for the Prophylaxis/Treatment for S. Pneumoniae Infection in Vulnerable Populations
Author: Gruenglas, et al.
Session Title: Poster Abstract Sessions
Session Dates: Friday, February 26 – Monday, March 1, 2021
Session Location: Virtual Poster Hall
Poster No: L30

A PDF copy of the abstract can be accessed here.

About ADMA Biologics, Inc.

ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Seite 1 von 2
ADMA Biologics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel